Kenvue has outpaced the broader market over the past year, and analysts remain cautiously optimistic about the stock’s ...

Kenvue Inc. (NYSE: KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its ...

Kenvue's board has nudged up its quarterly dividend by 1.2%, to 20.75 cents from 20.5 cents, extending the consumer-health company's royal payout status. The new quarterly rate, equal to 83 cents a ...

Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Kenvue's CEO and board member Thibaut Mongon has stepped down, it said on Monday, in the second big executive change at the consumer health company amid push by activist investors to boost performance ...

Por MICHELLE CHAPMANEl CEO de Kenvue dejará su cargo mientras el fabricante de las marcas Listerine y Band-Aid continúa con una revisión estratégica de sus negocios. Thibaut ...

Kenvue says that Thibaut Mongon is stepping down as its CEO as the maker of Listerine and Band-Aid brands continues with a strategic review of the company.

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, said Chief Executive Thibaut Mongon has departed and that the company is considering simplifying its portfolio amid a recent sales slump.

Kenvue appoints Kirk Perry as interim CEO after Thibaut Mongon's exit and launches strategic review to simplify operations.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Kenvue Inc. closed 11.16% below its 52-week high of $25.17, which the company achieved on May 8th.

(Reuters) -Kenvue's has fired CEO Thibaut Mongon, who has also stepped down from the board, the consumer health company said on Monday, marking its second major executive shake-up this year amid ...